Central nervous system involvement in AIDS-related lymphomas

Stefan K. Barta, Jitesh Joshi, Nicolas Mounier, Xiaonan (Nan) Xue, Dan Wang, Josep Maria Ribera, Jose Tomas Navarro, Christian Hoffmann, Kieron Dunleavy, Richard F. Little, Wyndham H. Wilson, Michele Spina, Lionel Galicier, Ariela Noy, Joseph A. Sparano

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Central nervous system (CNS) involvement is reportedly more common in acquired immunodeficiency syndrome (AIDS)-related lymphomas (ARL). We describe factors and outcomes associated with CNS involvement at baseline (CNSB) and relapse (CNSR) in 886 patients with newly diagnosed ARL. Of 886 patients, 800 received either intrathecal (IT) therapy for CNSB or IT prophylaxis. CNSB was found in 13%. CNSB was not associated with reduced overall survival (OS). There was no difference in the prevalence of CNSB between the pre-combination antiretroviral therapy (cART) and cART eras. 5·3% of patients experienced CNSR at a median of 4·2 months after diagnosis (12% if CNSB; 4% if not). Median OS after CNSR was 1·6 months. On multivariate analysis, only CNSB [hazard ratio (HR) 3·68, P = 0·005] and complete response to initial therapy (HR 0·14, P R. When restricted to patients without CNSB, IT CNS prophylaxis with 3 vs. 1 agent did not significantly impact the risk of CNSR. Despite IT CNS prophylaxis, 5% of patients experienced CNSR. Our data confirms that CNSR in ARL occurs early and has a poor outcome. Complete response to initial therapy was associated with a reduced frequency of CNSR. Although CNSB conferred an increased risk for CNSR, it did not impact OS.

Original languageEnglish (US)
Pages (from-to)857-866
Number of pages10
JournalBritish Journal of Haematology
Volume173
Issue number6
DOIs
StatePublished - Jun 1 2016

Fingerprint

Lymphoma
Acquired Immunodeficiency Syndrome
Central Nervous System
Recurrence
AIDS-Related Lymphoma
Survival
Therapeutics
Multivariate Analysis

Keywords

  • acquired immunodeficiency syndrome
  • AIDS-related lymphoma
  • central nervous system relapse
  • lymphoma
  • non-Hodgkin lymphoma

ASJC Scopus subject areas

  • Hematology

Cite this

Central nervous system involvement in AIDS-related lymphomas. / Barta, Stefan K.; Joshi, Jitesh; Mounier, Nicolas; Xue, Xiaonan (Nan); Wang, Dan; Ribera, Josep Maria; Navarro, Jose Tomas; Hoffmann, Christian; Dunleavy, Kieron; Little, Richard F.; Wilson, Wyndham H.; Spina, Michele; Galicier, Lionel; Noy, Ariela; Sparano, Joseph A.

In: British Journal of Haematology, Vol. 173, No. 6, 01.06.2016, p. 857-866.

Research output: Contribution to journalArticle

Barta, SK, Joshi, J, Mounier, N, Xue, XN, Wang, D, Ribera, JM, Navarro, JT, Hoffmann, C, Dunleavy, K, Little, RF, Wilson, WH, Spina, M, Galicier, L, Noy, A & Sparano, JA 2016, 'Central nervous system involvement in AIDS-related lymphomas', British Journal of Haematology, vol. 173, no. 6, pp. 857-866. https://doi.org/10.1111/bjh.13998
Barta, Stefan K. ; Joshi, Jitesh ; Mounier, Nicolas ; Xue, Xiaonan (Nan) ; Wang, Dan ; Ribera, Josep Maria ; Navarro, Jose Tomas ; Hoffmann, Christian ; Dunleavy, Kieron ; Little, Richard F. ; Wilson, Wyndham H. ; Spina, Michele ; Galicier, Lionel ; Noy, Ariela ; Sparano, Joseph A. / Central nervous system involvement in AIDS-related lymphomas. In: British Journal of Haematology. 2016 ; Vol. 173, No. 6. pp. 857-866.
@article{81c8c266034e403ebb59dde6eeb4dab2,
title = "Central nervous system involvement in AIDS-related lymphomas",
abstract = "Central nervous system (CNS) involvement is reportedly more common in acquired immunodeficiency syndrome (AIDS)-related lymphomas (ARL). We describe factors and outcomes associated with CNS involvement at baseline (CNSB) and relapse (CNSR) in 886 patients with newly diagnosed ARL. Of 886 patients, 800 received either intrathecal (IT) therapy for CNSB or IT prophylaxis. CNSB was found in 13{\%}. CNSB was not associated with reduced overall survival (OS). There was no difference in the prevalence of CNSB between the pre-combination antiretroviral therapy (cART) and cART eras. 5·3{\%} of patients experienced CNSR at a median of 4·2 months after diagnosis (12{\%} if CNSB; 4{\%} if not). Median OS after CNSR was 1·6 months. On multivariate analysis, only CNSB [hazard ratio (HR) 3·68, P = 0·005] and complete response to initial therapy (HR 0·14, P R. When restricted to patients without CNSB, IT CNS prophylaxis with 3 vs. 1 agent did not significantly impact the risk of CNSR. Despite IT CNS prophylaxis, 5{\%} of patients experienced CNSR. Our data confirms that CNSR in ARL occurs early and has a poor outcome. Complete response to initial therapy was associated with a reduced frequency of CNSR. Although CNSB conferred an increased risk for CNSR, it did not impact OS.",
keywords = "acquired immunodeficiency syndrome, AIDS-related lymphoma, central nervous system relapse, lymphoma, non-Hodgkin lymphoma",
author = "Barta, {Stefan K.} and Jitesh Joshi and Nicolas Mounier and Xue, {Xiaonan (Nan)} and Dan Wang and Ribera, {Josep Maria} and Navarro, {Jose Tomas} and Christian Hoffmann and Kieron Dunleavy and Little, {Richard F.} and Wilson, {Wyndham H.} and Michele Spina and Lionel Galicier and Ariela Noy and Sparano, {Joseph A.}",
year = "2016",
month = "6",
day = "1",
doi = "10.1111/bjh.13998",
language = "English (US)",
volume = "173",
pages = "857--866",
journal = "British Journal of Haematology",
issn = "0007-1048",
publisher = "Wiley-Blackwell",
number = "6",

}

TY - JOUR

T1 - Central nervous system involvement in AIDS-related lymphomas

AU - Barta, Stefan K.

AU - Joshi, Jitesh

AU - Mounier, Nicolas

AU - Xue, Xiaonan (Nan)

AU - Wang, Dan

AU - Ribera, Josep Maria

AU - Navarro, Jose Tomas

AU - Hoffmann, Christian

AU - Dunleavy, Kieron

AU - Little, Richard F.

AU - Wilson, Wyndham H.

AU - Spina, Michele

AU - Galicier, Lionel

AU - Noy, Ariela

AU - Sparano, Joseph A.

PY - 2016/6/1

Y1 - 2016/6/1

N2 - Central nervous system (CNS) involvement is reportedly more common in acquired immunodeficiency syndrome (AIDS)-related lymphomas (ARL). We describe factors and outcomes associated with CNS involvement at baseline (CNSB) and relapse (CNSR) in 886 patients with newly diagnosed ARL. Of 886 patients, 800 received either intrathecal (IT) therapy for CNSB or IT prophylaxis. CNSB was found in 13%. CNSB was not associated with reduced overall survival (OS). There was no difference in the prevalence of CNSB between the pre-combination antiretroviral therapy (cART) and cART eras. 5·3% of patients experienced CNSR at a median of 4·2 months after diagnosis (12% if CNSB; 4% if not). Median OS after CNSR was 1·6 months. On multivariate analysis, only CNSB [hazard ratio (HR) 3·68, P = 0·005] and complete response to initial therapy (HR 0·14, P R. When restricted to patients without CNSB, IT CNS prophylaxis with 3 vs. 1 agent did not significantly impact the risk of CNSR. Despite IT CNS prophylaxis, 5% of patients experienced CNSR. Our data confirms that CNSR in ARL occurs early and has a poor outcome. Complete response to initial therapy was associated with a reduced frequency of CNSR. Although CNSB conferred an increased risk for CNSR, it did not impact OS.

AB - Central nervous system (CNS) involvement is reportedly more common in acquired immunodeficiency syndrome (AIDS)-related lymphomas (ARL). We describe factors and outcomes associated with CNS involvement at baseline (CNSB) and relapse (CNSR) in 886 patients with newly diagnosed ARL. Of 886 patients, 800 received either intrathecal (IT) therapy for CNSB or IT prophylaxis. CNSB was found in 13%. CNSB was not associated with reduced overall survival (OS). There was no difference in the prevalence of CNSB between the pre-combination antiretroviral therapy (cART) and cART eras. 5·3% of patients experienced CNSR at a median of 4·2 months after diagnosis (12% if CNSB; 4% if not). Median OS after CNSR was 1·6 months. On multivariate analysis, only CNSB [hazard ratio (HR) 3·68, P = 0·005] and complete response to initial therapy (HR 0·14, P R. When restricted to patients without CNSB, IT CNS prophylaxis with 3 vs. 1 agent did not significantly impact the risk of CNSR. Despite IT CNS prophylaxis, 5% of patients experienced CNSR. Our data confirms that CNSR in ARL occurs early and has a poor outcome. Complete response to initial therapy was associated with a reduced frequency of CNSR. Although CNSB conferred an increased risk for CNSR, it did not impact OS.

KW - acquired immunodeficiency syndrome

KW - AIDS-related lymphoma

KW - central nervous system relapse

KW - lymphoma

KW - non-Hodgkin lymphoma

UR - http://www.scopus.com/inward/record.url?scp=84973601413&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84973601413&partnerID=8YFLogxK

U2 - 10.1111/bjh.13998

DO - 10.1111/bjh.13998

M3 - Article

C2 - 27062389

AN - SCOPUS:84973601413

VL - 173

SP - 857

EP - 866

JO - British Journal of Haematology

JF - British Journal of Haematology

SN - 0007-1048

IS - 6

ER -